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Abstract—The ultrasound contrast agent based on a poly lactic 
acid (PLA) was prepared by combining an ultrasound method 
and a Shirasu Porous Glass (SPG) membrane emulsification 
technique. An aqueous phase containing ammonium bicarbonate 
was used as the internal water phase (W1), and PLA and Span 80 
were dissolved in a solvent of dichloromethane (DCM), which 
was used as the oil phase (O). These two solutions were probe 
sonicated to form a W1/O primary emulstion. The primary 
emulsion was permeated through the uniform pores (1.1 μm) of 
an SPG membrane into the external water phase (W2) by the 
pressure of nitrogen gas to form the uiniform W1/O/W2 droplets. 
After DCM was evaporated, the hardened PLA microcapsules 
were further formulated into a lyophilized powder containing 
decafluorobutane gas. SEM image demonstrated that the PLA 
microcapsules were sphere-shaped and internally hollow with an 
average diameter ranging from 1.99 to 3.58 μm. In vitro, the PLA 
contrast agents showed high acoustic enhancement properties, 
the enhancement increased nonlinearly with dose, and the 
minimal loss (less than 5 dB) of signal was observed over 20 min 
of analysis at 37 ºC, the maximum acoustic enhancement was 45 
dB, which significantly higher (p<0.01) compared to a value of 28 
dB for those prepared by a conventional solvent evaporation 
method. In conclusion, the hollow PLA microcapsules prepared 
by the novel method have the characteristics desirable for an 
intravenously administered ultrasound contrast agents. 
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I.  INTRODUCTION 
Ultrasound contrast agents (UCA) can provide enhanced 
scattering signatures to distinguish the acoustic scattering 
signatures of blood from the surrounding tissues [1, 2]. To 
become a viable UCA, certain properties are desirable [3, 4], 
these include being nontoxic, easy intravenously 
administration, small enough to traverse the capillaries, stable 
enough to provide enhancement over multiple cardiac cycles, 
and higher acoustically responsive. This property allows UCA 
to act as blood pool markers with a behavior similar to that of 
red blood cells.  
Poly lactic acid (PLA) is a popular biodegrade-able and 
bioconsistent polymer that has been approved by the FDA for 
use in sutures, microcapsule, micobubble and others in 
intravenous injection. PLA can slowly be degraded by non-
enzymatihydrolysis into lactic acids which is a natural body 
metabolite and can be degraded by enzymes to carbon dioxide 
and aqueous. Polymer (e.g PLA or PLGA)-based UCA showed 
more stability in vivo, high natural resonance frequency, and 
acquired ideal scattering intensity under high emitted frequency 
[5, 6]. Nevertheless, the polymer-made UCA has relatively 
hard shell, a few of big size of UCA may alter the blood flow 
and impede the capillary circulation. 
From an acoustic perspective, the average size of UCA 
should be as large as possible, as larger microbubbles generate 
more intense ultrasound signals [7]. However, most of UCA 
should be no larger than the size of a red blood cell (7-8 μm in 
diameter). Several techniques, such as double emulsion 
combining with solvent evaporation, ultrasonication and spray 
drying are used to produce polymer-based UCA, the size 
distribution of UCA obtained is relatively broad, which is 
unfavorable for intravenously administration. Therefore, 
developing a method which can provide the uniform diameter 
of UCA composed of biodegradable polymers with better 
acoustic enhancement properties is highly appreciative. 
The SPG membrane emulsification technique is a 
promising technique first proposed by Nakashima [8] to 
prepare uniform sized emulsion and later developed by Ma et 
al. [9, 10] to prepare uniform microspheres by polymerizing 
uniform monomer droplets. However, the SPG membrane 
emulsification technique has not been used to prepare PLA 
ultrasound contrast agents. 
II. MATERIALS AND METHOD 
A. Materials 
PLA (Mw = 10,000) was obtained from the Institute of 
Medical Instrument (Shandong, China). Decafluorobutane 
(DFB) gas was provided by the Linggas. LTD (Beijing, China). 
Dichloromethane (DCM), polysorbate 80, ammonium 
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bicarbonate, Poly(vinyl alcohol) (PVA, degree of 
polymerization 1700, degree of hydrolysis 88.5%) used as a 
stabilizer in the external water phase were purchased from 
Xiamen Chemical Reagents Company (Xiamen, China). All 
other reagents and solvents were of analytical grade. 
B. Preparation of PLA ultrasound contrast agents 
Fast mini Kit (KH-125) for emulsification was purchased 
from SPG Technology Co.,TLD. A tubular membrane with an 
average pore size of 1.1 μm was used. Preparation process was 
as follow: 5 mL of inner aqueous phase containing 0.125 g 
ammonium bicarbonate (w1) was injected into 50 mL DCM oil 
phase in which was dissolved 1.25 g PLA10000 and 0.5 mL 
Span 80, then this solution was probe sonicated at 80 W for 10s 
and repeated 5 times to form a w1/o primary emulsion. An 
aqueous phase (500 mL) containing 1% PVA (w/v) and 0.5% 
(w/v) SDS was used as the external water phase (w2). The w1/o 
emulsion was permeated through the uniform pores of an SPG 
membrane into the external water phase by the pressure of 
nitrogen gas to form the uniform-sized droplets. Then, DCM 
was evaporated at room temperature for 24 h under a gentle 
stirring at a rate of 200 rpm. After DCM was evaporated, the 
hardened PLA microcapsules were collected by centrifugation 
and washed with distilled water three times and the purified 
PLA microcapsules were further processed to form PLA 
ultrasound contrast agents by dispersing the microcapsules in 
aqueous vehicle followed by deaggregation, sieving, filling, 
freezing, and lyophilization. An aqueous vehicle was prepared 
containing mannitol (28 g/L water) and polysorbate 80 (0.82 
g/L water). The purified PLA microcapsules were dispersed in 
the vehicle at a concentration of 19.6 mg/mL. The dispersion 
was deaggregated using a stainless steel blender at rate of 1000 
rmp, sieved through disposable infusion apparatus. The sieved 
dispersion was filled into vials (10 mL fill in 20 mL vials), 
partially stoppered, and frozen in a -80 ºC freezer. Following 
freezing, the vials were lyophilized in vacuum refrigerant drier 
(Labconco Free Zone). At the end of lyophilization, the 
chamber was isolated, and DFB gas was backfilled into the 
vials prior to completely stoppering.  
  PLA contrast agents (the finished dosage form of vials 
containing PLA microcapsules, DFB, mannitol and polysorbate 
80) were stored at 2-8 ºC. For reconstitution, 10 mL of sterile 
water was added into a vial of the agent, and the vial was 
shaken. 
To compare the results, those obtained by an ultrasound 
method, the microcapsules were also prepared by the solvent 
evaporation method. The procedure for PLA microcapsules by 
the solvent evaporation method was similar to the process 
mentioned above except that the w1/o emulsion droplets were 
poured into an aqueous phase (500 mL) containing 1% PVA 
and 0.5% SDS and homogenized at a rate of 1000 rpm.  
To observe the cross-section of PLA microcapsule, the 
w1/o/w2 the double emulsion droplets yielded by the 
homogenizer were further stirred by a high shear mixer with 
whirling blades at rate of 10000 rpm. 
C. Scanning electron microscopy (SEM) of PLA 
microcapsule 
SEM was used to examine the surface morphology and 
cross sections of the microcapsules. The dried microcapsules 
were mounted on metal stubs with double-sided electrical tape. 
They were gold coated under reduced pressure with a sputter 
coater before being viewed under the SEM at 20 kV. 
 
D. Determination of size distribution 
Zetasizer (Nano-ZS, Malven) was used to measure the size 
distribution of PLA microcapsules. 
 
E. In vitro acoustic test 
 
Figure 1.  In vitro acoustic test setup 
An in vitro acoustic test was performed by exposing a 
sample of the PLA contrast agents to a focused, pulsed 
ultrasound beam, using a system as shown in Fig.1. The time-
response curves were constructed to measure the echogenicity 
of the microcapsules. A pulser-receiver shock-excited a 
focused ultrasound transducer (2.25 MHz, Panametrics, 
PR5800, Watertown, MA) sending a pulse of ultrasound into a 
suspension of microcapsules, which were contained in a 
cylindrical sample chamber (50 mL). The custom-made sample 
chamber was made from one of 50-mL plastic centrifuge tubes 
with open mouth sealed with polyester film and served as an 
acoustic window. The chamber was situated in a temperature 
controlled deionized water bath adjusted to 37ºC, and the 
transducer was submerged in the bath and focused through an 
acoustic window of the chamber. The backscattered signal was 
received by the same transducer, and the returned signal was 
then amplified by the pulser-receiver unit. The amplified signal 
was passed to a digital oscilloscope (GDS-806C, Instek, 
Taiwan, China) for digitization at 100 MSa/s. The operation of 
the digital oscilloscope and ultrasonic pulser-receiver were 
controlled and analyzed by a PC using Lab View (National 




further processed using the method reported by J.A. Straub et 
al. [11] 
The water tank was equipped with a stable mounting for the 
cylindrical sample chamber. The agents were diluted in 
different ratio (1:200, 1:500 and 1:1000) with phosphate 
buffered saline (PBS) pH 7.4, the concentration of agents 
evaluated as 0.098, 0.0392, 0.0196 mg/mL, respectively. In 
comparison, the agent prepared by un ultrasound method was 
diluted (1:200) with PBS, the concentration of the agent was 
0.098 mg/mL. 
  The acoustic enhancement was measured immediately 
after the agents were diluted in different concentration, time 
was recorded as zero minutes, and the acoustic enhancement 
was measured at selected time points over 20 minutes. The 
time-response curve values are based on an average of three 
different sample preparations. The reference (PBS) was taken 
as an average of three values. 
F. Statistical analysis 
The results were expressed as mean ± S.E.M and Student’s 
t-test were used to compare duration of enhancement and 
parameters derived from the time-intensity curves for three 
PLA contrast agents. Differences between agents were 
considered significant when P < 0.05. 
III. RESULTS 
A. Physical Characterization of PLA contrast agent 
 
Figure 2.  SME image of surface and cross-sections of 
representative PLA microcapsules 
The SEM photographs of surface and cross section of PLA 
microcapsules are shown in Fig.2, which demonstrates that the 
microcapsules were essentially spherical in shape and reveal 
internally hollow microcapsules instead of internally porous 
microcapsules with multiple internal voids. 
  A particle size distribution of PLA contrast agents 
obtained by combining an ultrasound method and a SPG 
membrane emulsification technique ranged from 1.99 to 3.58 
μm. While those prepared by the solvent evaporation method 
presented very broad size distribution and ranged from 955 nm 
to 6.44 μm. 
 
B. Functional Characterization of PLA contrast agent 
The relative acoustic backscatter data at 2.25 MHz in vitro 
are shown in Fig. 3. The PLA contrast agents display 
enhancements of up to 26 dB, 37 dB and 45 dB with dose of 
0.0196, 0.0392, 0.098 mg/mL, respectively，the enhancement 
increased nonlinearly with dose increase. While the PLA 
contrast agents obtained by the ultrasound method had 
maximum acoustic enhancement of 28 dB, being significantly 
lower than that of PLA contrast agents prepared by the novel 
method at same dose of 0.098 mg/mL. The acoustic backscatter 
for PLA contrast agents at different of concentrations were all 
stable and minimal loss of signal (less than 5 dB) was observed 
over the 20 min duration of analysis at 37 ºC, much longer than 
would be needed for diagnostic imaging. 
 
Figure 3.  In vitro time response curve (20 min) for acoustic 
enhancement of different concentration of PLA contrast agents obtained by 
combining un ultrasound method and a SPG membrane emulsification 
technique: (■) 0.0196 mg/mL, (●) 0.0392 mg/mL, (▲) 0.098 mg/mL; PLA 
contrast agent prepared by un ultrasound method: (▼) 0.098 mg/mL, used as 
comparison agents, results are mean ± S.E.M. of three samples. **p< 0.01 
Vs comparison agents 
 
IV. DISCUSSION AND CONCLUSION 
The most important to the function of an ultrasound 
contrast agent in vivo is the intensity of the backscattered 
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acoustic signal, which is used to create the ultrasound image. In 
vitro acoustic analysis of PLA contrast agents was performed 
at 2.25 MHz, as this is in the range of acoustic frequencies used 
for standard cardiac imaging. The results indicate that the PLA 
contrast agents obtained by the novel method showed the 
maximum acoustic enhancement of 45 dB, which significantly 
higher (p <0.01) compared to a value of 28 dB for those 
prepared by the conventional method for same dose of 
suspending medium. As backscatter is reported in dB (a log-
based scale), the data indicate that the integrated backscattered 
power is more than two orders of magnitude higher for PLA 
contrast agents than that obtained by the conventional method 
within the start of the analysis. This phenomenon may be due 
to the fact that higher uniform size of PLA microcapsules 
generates more intense ultrasound signals. 
  In conclusion, the hollow PLA microcapsules prepared by 
the novel method have the characterisitics desirable for an 
intravenously administered ultrasound contrast agents. 
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